News › Funding

BioSapien extends its pre-Series A round again to over $8 million

July 7, 2025
BioSapien secures $5.5M pre-Series A for its drug delivery platform

Abu Dhabi-based BioSapien has once again extended its pre-Series A round, bringing the total count to over $8 million.

Proceeds will be used for further driving of product development, manufacturing, and clinical trials.

Also, the company will use the funds for appointments of world-class talent to shape the future of precision medicine, including Joseph Borrello, PhD, as Chief Technology Officer; and Sonia Ramamoorthy, MD, MBA, FACS, as Head of Medical Affairs.

BioSapien is a clinical-stage biotech firm pioneering the future of localised drug delivery. Its flagship technology, MediChip, enables sustained, targeted release of chemotherapeutics directly at tumor sites — thus minimizing systemic toxicity and revolutionizing cancer care.

The funding yet again reinforces the UAE's status as a global healthcare innovation hub that fosters medical innovation.

Funding 💰

Round ~$1M
Pre-Series A extension
Lead investor(s) Globivest

Quotes 💬

“
Two of the greatest challenges for young, fast-growing companies are establishing a strong balance sheet and attracting high-quality talent. Therefore, I am delighted to announce an extension of BioSapien's pre-Series A funding round. As a female-led healthcare fund in the MENA region - and backed by EU pharma - we are proud to have Globivest as an investor and strategic partner. Similarly, it gives me great pleasure to welcome new, world-class colleagues across all tiers of the Company. A business is only as good as its people - so it is thrilling to be joined by such high-quality, diverse talent. Together, we will shape a future where precision medicine is both globally impactful and locally accessible.
— Dr. Khatija Ali, CEO of BioSapien
“
At Globivest, we back companies that don't just promise innovation - they deliver transformative, science-backed solutions with the power to shift paradigms. BioSapien's MediChip platform is a breakthrough in localized cancer treatment - scalable, precise, and deeply aligned with our One Health mission. We're proud to support Dr. Khatija Ali and her team as they build the future of accessible precision medicine.
— Dr. Laura-Joy Boulos, Partner at Globivest

About 🏢

BioSapien is a biotechnology company specializing in innovative cancer treatments. Its flagship product, MediChip, is a 3D-printed, biodegradable implant designed to deliver chemotherapy drugs directly to tumor sites, aiming to minimize systemic side effects commonly associated with traditional chemotherapy. This localized approach targets cancer cells more precisely and enhances patients' quality of life during treatment. The company holds global patents for its platform, with expirations set for 2039. BioSapien's mission is to advance human well-being through innovative solutions, with a goal to treat over one million patients by 2035. In addition to Abu Dhabi, the company has an office in San Diego, California. more

Latest @ DH Arab

Cleveland Clinic Abu Dhabi introduces novel stroke treatment

Tunisia's Najda digital platform launches to tackle heart attacks

Qatar HMC's new Lbaih app surpasses 100K downloads

Abu Dhabi to enhance national newborn screening programme

Mental health center in Jeddah unveils robot to support addiction recovery

💡Did you know?

You can take your DHArab experience to the next level with our Premium Membership.
👉 Click here to learn more

🛠️Featured tool

Easy-Peasy Easy-Peasy
An all-in-one AI tool offering the ability to build no-code AI Bots, create articles & social media posts, convert text into natural speech in 40+ languages, create and edit images, generate videos, and more.
👉 Click here to learn more